Raphael Pharmaceutical (RAPH) Accumulated Expenses (2021 - 2025)

Raphael Pharmaceutical has disclosed Accumulated Expenses across 5 years of filings, most recently posting $343000.0 for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $343000.0, down 8.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $343000.0 (down 8.53% YoY), and the FY2025 annual result was $343000.0, down 8.53% from the prior year.
• Accumulated Expenses came in at $343000.0 for Q4 2025 at Raphael Pharmaceutical, down from $375000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $375000.0 in Q4 2024 to a low of $25000.0 in Q4 2023.
• The 5-year median for Accumulated Expenses is $165000.0 (2021), against an average of $212000.0.
• Across the five-year window, Accumulated Expenses plunged 83.55% in 2023 and surged 1400.0% in 2024, its largest moves.
• Raphael Pharmaceutical's Accumulated Expenses stood at $165000.0 in 2021, then retreated by 7.88% to $152000.0 in 2022, then slumped by 83.55% to $25000.0 in 2023, then soared by 1400.0% to $375000.0 in 2024, then declined by 8.53% to $343000.0 in 2025.
• The last three Accumulated Expenses figures came in at $343000.0 (Q4 2025), $375000.0 (Q4 2024), and $25000.0 (Q4 2023), per Business Quant data.